{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,25]],"date-time":"2026-03-25T00:05:34Z","timestamp":1774397134607,"version":"3.50.1"},"reference-count":30,"publisher":"BMJ","issue":"6","license":[{"start":{"date-parts":[[2025,4,11]],"date-time":"2025-04-11T00:00:00Z","timestamp":1744329600000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100009128","name":"Research for Patient Benefit Programme","doi-asserted-by":"publisher","award":["PB-PG-0817-20044"],"award-info":[{"award-number":["PB-PG-0817-20044"]}],"id":[{"id":"10.13039\/501100009128","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["Emerg Med J"],"accepted":{"date-parts":[[2025,3,6]]},"published-print":{"date-parts":[[2025,6]]},"abstract":"<jats:sec>\n<jats:title>Background<\/jats:title>\n<jats:p>The pain of renal colic, mediated in part by ureteral spasm and inflammation, is often severe and difficult to control. Salbutamol has been shown to cause ureteral relaxation, but its effects on the pain of renal colic have never been studied. The objective of this trial was to investigate whether the use of intravenous salbutamol in addition to standard analgesia was associated with greater pain reduction compared with standard analgesia alone in patients presenting to emergency departments (EDs) with renal colic.<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>Methods<\/jats:title>\n<jats:p>This single-centre, double-blind, phase II, randomised, placebo-controlled trial recruited adult (\u226518 years) ED patients with clinically suspected renal colic. Participants were randomised in a 1:1 ratio to receive either 250 \u00b5g of intravenous salbutamol or a placebo (0.9% sodium chloride). The primary outcome was the difference in the change in pain scores (measured on a 100\u2009mm Visual Analogue Scale) from baseline to 30\u2009min following trial treatment administration in participants with subsequently confirmed renal colic. A modified intention-to-treat analysis was undertaken for the primary population of participants with confirmed renal colic.<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>Results<\/jats:title>\n<jats:p>Consent was obtained from 151 patients; 108 participants with confirmed renal colic were included in the primary outcome analysis. There was no statistical difference between groups in median change in pain score at 30\u2009min (salbutamol group \u221218\u2009mm (IQR \u221225 to \u22123), placebo group \u221213\u2009mm (IQR \u221233 to \u22121), difference 5\u2009mm (95%\u2009CI \u221216 to 6, p=0.575)). No significant differences were found in the secondary outcomes related to pain, patient satisfaction or opiate requirement.<\/jats:p>\n<jats:p>More adverse events (AEs) were observed in the salbutamol group (65) compared with placebo (42, p=0.02); no unexpected AEs were identified.<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>Conclusions<\/jats:title>\n<jats:p>This trial has not identified a clinically or statistically significant benefit from the addition of intravenous salbutamol to standard care for patients presenting to an ED with pain caused by renal colic.<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>Trial registration numbers<\/jats:title>\n<jats:p>The trial was registered with the European Union Drug Regulating Authorities Clinical Trials Database (EudraCT), reference 2018-004305-11. It was also registered with the ISRCTN Registry, reference 14552440.<\/jats:p>\n<\/jats:sec>","DOI":"10.1136\/emermed-2024-214326","type":"journal-article","created":{"date-parts":[[2025,4,11]],"date-time":"2025-04-11T17:20:19Z","timestamp":1744392019000},"page":"378-386","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":3,"title":["Salbutamol for analgesia in renal colic: a prospective, randomised, placebo-controlled phase II trial"],"prefix":"10.1136","volume":"42","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6004-6244","authenticated-orcid":false,"given":"Graham D","family":"Johnson","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4191-9024","authenticated-orcid":false,"given":"Andrew","family":"Tabner","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Apostolos","family":"Fakis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6559-5960","authenticated-orcid":false,"given":"Rachelle","family":"Sherman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Victoria","family":"Chester","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrew","family":"Skeggs","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fran","family":"Game","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Richard","family":"Jackson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1701-0577","authenticated-orcid":false,"given":"Suzanne M","family":"Mason","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"239","published-online":{"date-parts":[[2025,4,11]]},"reference":[{"key":"2025062400001801000_42.6.378.1","doi-asserted-by":"publisher","DOI":"10.3390\/ph3051304"},{"key":"2025062400001801000_42.6.378.2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ucl.2007.04.003"},{"key":"2025062400001801000_42.6.378.3","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMcp030813"},{"key":"2025062400001801000_42.6.378.4","unstructured":"Electronic Medicines Compendium . Summary of product characteristics: ventolin 0.5mg in 1ml solution for injection. 2015. Available: http:\/\/www.medicines.org.uk\/emc\/medicine\/3637\/SPC\/"},{"key":"2025062400001801000_42.6.378.5","doi-asserted-by":"crossref","DOI":"10.1016\/j.urology.2010.12.045","article-title":"Ureteral selectivity of intravenous \u03b2-adrenoceptor agonists in pig model of acute ureteral obstruction: comparison of KUL-7211, a selective \u03b22\/\u03b23 agonist, with isoproterenol, terbutaline, and CL-316243","volume":"77","author":"Wanajo","year":"2011","journal-title":"Urology"},{"key":"2025062400001801000_42.6.378.6","doi-asserted-by":"publisher","DOI":"10.1007\/s00240-005-0475-5"},{"key":"2025062400001801000_42.6.378.7","article-title":"Endoluminal pharmacologic stimulation of the upper urinary tract","volume":"60","author":"Jakobsen","year":"2013","journal-title":"Dan Med J"},{"key":"2025062400001801000_42.6.378.8","doi-asserted-by":"publisher","DOI":"10.1111\/iju.12093"},{"key":"2025062400001801000_42.6.378.9","doi-asserted-by":"publisher","DOI":"10.1007\/s00240-006-0069-x"},{"key":"2025062400001801000_42.6.378.10","doi-asserted-by":"publisher","DOI":"10.1016\/S0022-5347(05)66049-1"},{"key":"2025062400001801000_42.6.378.11","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2008.03.092"},{"key":"2025062400001801000_42.6.378.12","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2125.1986.tb02939.x"},{"key":"2025062400001801000_42.6.378.13","doi-asserted-by":"crossref","unstructured":"Holdgate A , Pollock T . Nonsteroidal anti-inflammatory drugs (NSAIDs) versus opioids for acute renal colic. Cochrane Database Syst Rev 2004. doi:10.1002\/14651858.CD004137.pub2","DOI":"10.1002\/14651858.CD004137.pub2"},{"key":"2025062400001801000_42.6.378.14","unstructured":"Electronic Medicines Compendium . Summary of product characteristics: morphine sulphate 10mg\/ml solution for injection. 2014. Available: http:\/\/www.medicines.org.uk\/EMC\/medicine\/13143\/SPC\/Morphine+Sulphate+10mg+ml+Injection+BP\/"},{"key":"2025062400001801000_42.6.378.15","unstructured":"Electronic Medicines Compendium . Summary of product characteristics: voltarol suppositories. 2017. Available: https:\/\/www.medicines.org.uk\/emc\/medicine\/1344"},{"key":"2025062400001801000_42.6.378.16","doi-asserted-by":"publisher","DOI":"10.1136\/emermed-2018-207881"},{"key":"2025062400001801000_42.6.378.17","doi-asserted-by":"crossref","DOI":"10.1186\/s13063-022-06225-9","article-title":"Salbutamol for analgesia in renal colic: study protocol for a prospective","volume":"23","author":"Johnson","year":"2022","journal-title":"Trials"},{"key":"2025062400001801000_42.6.378.18","first-page":"191","volume-title":"The Short-Form MCGill Pain Questionnaire","volume":"30","author":"Melzack","year":"1987"},{"key":"2025062400001801000_42.6.378.19","doi-asserted-by":"crossref","unstructured":"Machin D , Campbell MJ , Tan SB , et al . Sample size tables for clinical studies. In: Wiley-Blackwell. 2008: 49. Available: https:\/\/onlinelibrary.wiley.com\/doi\/book\/10.1002\/9781444300710","DOI":"10.1002\/9781444300710"},{"key":"2025062400001801000_42.6.378.20","doi-asserted-by":"publisher","DOI":"10.1016\/S0196-0644(96)70238-X"},{"key":"2025062400001801000_42.6.378.21","doi-asserted-by":"publisher","DOI":"10.1067\/mem.2001.118863"},{"key":"2025062400001801000_42.6.378.22","doi-asserted-by":"publisher","DOI":"10.3310\/hta18380"},{"key":"2025062400001801000_42.6.378.23","doi-asserted-by":"crossref","DOI":"10.1186\/s13063-024-07935-y","article-title":"Pragmatic randomized controlled trials: strengthening the concept through a robust international collaborative network: PRIME-9-Pragmatic Research and Innovation through Multinational Experimentation","volume":"25","author":"Omerovic","year":"2024","journal-title":"Trials"},{"key":"2025062400001801000_42.6.378.24","article-title":"Alpha-blockers as medical expulsive therapy for ureteral stones","volume":"4","author":"Campschroer","year":"2018","journal-title":"Cochrane Database Syst Rev"},{"key":"2025062400001801000_42.6.378.25","doi-asserted-by":"publisher","DOI":"10.1177\/8755122517750398"},{"key":"2025062400001801000_42.6.378.26","doi-asserted-by":"publisher","DOI":"10.1136\/thx.2004.025411"},{"key":"2025062400001801000_42.6.378.27","doi-asserted-by":"crossref","DOI":"10.1186\/s13030-017-0089-5","article-title":"Tolerable pain reduces gastric fundal accommodation and gastric motility in healthy subjects: a crossover ultrasonographic study","volume":"11","author":"Hasuo","year":"2017","journal-title":"Biopsychosoc Med"},{"key":"2025062400001801000_42.6.378.28","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2125.1975.tb00566.x"},{"key":"2025062400001801000_42.6.378.29","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajem.2019.158483"},{"key":"2025062400001801000_42.6.378.30","doi-asserted-by":"publisher","DOI":"10.1007\/s40122-023-00530-0"}],"container-title":["Emergency Medicine Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/emermed-2024-214326","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,26]],"date-time":"2025-06-26T11:49:16Z","timestamp":1750938556000},"score":1,"resource":{"primary":{"URL":"https:\/\/emj.bmj.com\/lookup\/doi\/10.1136\/emermed-2024-214326"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,11]]},"references-count":30,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2025,5,22]]},"published-print":{"date-parts":[[2025,6]]}},"alternative-id":["10.1136\/emermed-2024-214326"],"URL":"https:\/\/doi.org\/10.1136\/emermed-2024-214326","relation":{},"ISSN":["1472-0205","1472-0213"],"issn-type":[{"value":"1472-0205","type":"print"},{"value":"1472-0213","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,4,11]]}}}